Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)
NCT07721649 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 482
Last updated 2026-07-23
Summary
The aim of this study is to evaluate the effect of offering intrahospital influenza vaccination as an adjunct to active counseling during the index hospitalization to adult patients hospitalized for acute coronary syndrome (ACS) or congestive heart failure (CHF), compared with active counseling alone, on influenza vaccination rates in patients at high cardiovascular risk.
Patients are randomized 1:1 to either an offer of bedside intrahospital influenza vaccination according to the recommendations of the German Standing Vaccination Committee (STIKO) in addition to standardized active counseling (intervention group), or standardized active counseling plus the standard-of-care recommendation for ambulatory vaccination in the discharge papers (control group). The primary endpoint is the influenza vaccination rate at the end of the index season (March 31).
Conditions
- Acute Coronary Syndrome
- Heart Failure
- Influenza, Human
- Cardiovascular Diseases
- Vaccination Refusal
Interventions
- BIOLOGICAL
-
Intrahospital seasonal influenza vaccination offer
Offer of bedside vaccination against seasonal influenza during the index hospitalization, administered in a standardized manner by trained treating physicians according to the latest STIKO recommendations and the respective product information. The appropriate vaccine is selected according to current recommendations (e.g., high-dose quadrivalent vaccine for patients aged 60 years and older, standard-dose quadrivalent vaccine otherwise). Vaccination is offered from September 1 to February 28 of the respective influenza season.
- BEHAVIORAL
-
Standardized active influenza vaccination counseling
Standardized active counseling on influenza vaccination using a cardiovascular gain-framed information sheet, including the recommendation to be vaccinated and the opportunity to discuss vaccination with the treating physician. Counseling is provided to all patients in both arms after completion of the baseline 7C questionnaire and prior to randomization.
- BEHAVIORAL
-
Standard of care discharge recommendation for ambulatory vaccination
Current standard of care in Germany: the recommendation to obtain ambulatory influenza vaccination from the primary care physician, stated in the discharge papers.
Sponsors & Collaborators
- collaborator INDUSTRY
-
Stephan Baldus
lead OTHER
Principal Investigators
-
Stephan Baldus, Prof. Dr. med. · Clinic III for Internal Medicine, University Hospital of Cologne
-
Sebastian Heyne, Dr. med. · Clinic III for Internal Medicine, University Hospital of Cologne
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-09-30
- Primary Completion
- 2028-03-31
- Completion
- 2029-06-30
Countries
- Germany
Study Locations
More Related Trials
-
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
NCT02787044 ·Status: COMPLETED ·Phase: PHASE4
-
Influenza Vaccination After Acute Coronary Syndrome
NCT07259252 ·Status: RECRUITING ·Phase: NA
-
VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
NCT02268500 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease
NCT06508437 ·Status: COMPLETED ·Phase: PHASE4
-
Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™
NCT00306982 ·Status: COMPLETED
-
Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™
NCT00377611 ·Status: COMPLETED ·Phase: PHASE4
-
WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.
NCT07386509 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate
NCT00374842 ·Status: COMPLETED ·Phase: PHASE2
-
Timing of Influenza Vaccination in Patients With Heart Failure
NCT05507502 ·Status: UNKNOWN ·Phase: NA
-
InFLUenza and the HEART An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection
NCT05084846 ·Status: COMPLETED
-
Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake
NCT05542004 ·Status: COMPLETED ·Phase: NA
-
Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly
NCT00383526 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population
NCT00318149 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population
NCT00318058 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Influenza Vaccination of Healthcare Workers (HCW) on the Risk of Influenza in Patients Hospitalized in Short Stays Units
NCT02198638 ·Status: COMPLETED ·Phase: NA
-
Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes
NCT04001504 ·Status: COMPLETED ·Phase: PHASE3
-
Influenza Vaccination of Nursing Home Workers.
NCT00359554 ·Status: TERMINATED ·Phase: NA
-
Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups
NCT00711295 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate
NCT00363077 ·Status: COMPLETED ·Phase: PHASE2
-
Response to Influenza Virus Vaccination in Patients Immunocompromised Due to Chemotherapy
NCT01000246 ·Status: COMPLETED ·Phase: NA
-
Herd Immunity and Influenza Vaccine Uptake
NCT03748160 ·Status: COMPLETED ·Phase: NA
-
Adjuvanted Influenza Vaccination in U.S. Nursing Homes
NCT02882100 ·Status: COMPLETED ·Phase: PHASE4
-
The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases
NCT00607217 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population
NCT00377585 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012
NCT01344057 ·Status: COMPLETED ·Phase: PHASE2